Foreword by E. Donnall Thomas. v
Foreword by David J. Weatherall. vii
Preface. ix
Contributors. xv
Part I. Molecular Markers.
Selecting the Right Targets for Cancer Therapy. Miguel H. Bronchud and William P. Peters. 3
Clinical Importance of Prognostic Factors: Moving from Scientifically. Interesting to Clinically Useful Daniel F. Hayes. 29
Genetic Markers in Sporadic Tumors. S. Birindelli, A. Aiello, C. Lavarino, G. Sozzi, Silvana Pilotti, and Marco A. Pierotti. 45
Cellular and Tissue Markers in Solid Tumors. Thomas Lin da hi, Torbjon Notberg, Gunnar Astrom, Sigrid Sjogren, and C. Jonas Bergh. 95
Circulating Tumor Markers. Alan Horwich and Gill Ross. 111
Part II. Diseased Regulatory Pathways.
Growth Factor-Signaling Pathways in Cancer Daniel Kalderon. 127
Estrogen Action and Breast Cancer. Hong Liu and V. Craig Jordan. 169
Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics Leonardo Brizuela, Jerio Gyuris, and Muzammil Mansuri. 197
Apoptosis Pathways: Clinical Relevance. Caroline Archer, Peter Trott, and Mitchell Dowsett. 237
DNA Repair Pathways: Mechanisms and Defects in the Maintenance of Genome Stability Murray O. Robinson. 257
Angiogenesis Switch Pathways. Jatime Piulats and Francesc Mitjans. 271
Invasion and Metastasis. Maria Rosa Bani and Rafaella Giavazzi. 297
Molecular Pathways of Drug Resistance. Christos Talis, Carlos G. Ferreira, Herbert M. Pineda, and. Giuseppe Giaccone. 323
Part III. Future Directions.
Antitumor Immunity as Therapy for Human Cancer. Angela A. Cardoso. 359
Emerging Technologies: Molecular Targets and the Drug Delivery Process. Matthew Moyle and Michael Palazzolo. 395
Emerging Molecular Therapies for Cancer. Karol Sikora. 411
Emerging Molecular Therapies: Small-Molecule Drugs. Paul Workman. 421
Glossary. 439
Index. 443